Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment.
Absenteeism
Health-related quality of life
Healthcare costs
Migraine
Presenteeism
Preventive medicine
Treatment failure
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
25
05
2023
accepted:
16
08
2023
medline:
25
8
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Data are limited regarding the combined impact of headache frequency and failure of preventive medication (efficacy and/or tolerability) on the humanistic/economic burden of migraine. A retrospective, cross-sectional analysis of 2020 National Health and Wellness Survey (NHWS) data was conducted. An opt-in online survey identified adults in France, Germany, Italy, Spain, and United Kingdom with self-reported physician-diagnosed migraine. Participants with ≥ 4 monthly headache days (MHDs) were stratified by prior preventive medication use/failure (preventive naive; 0-1 failure; ≥ 2 failures). Quality-of-life and economic outcomes were compared among groups using generalized linear modeling. Among individuals with ≥ 4 MHDs (n = 1106), the NHWS identified 298 (27%) with ≥ 2 failures, 308 (28%) with 0-1 failure, and 500 (45%) as preventive naive. Individuals with ≥ 2 failures versus preventive-naive individuals had significantly lower scores on the 12-Item Short Form Survey Physical Component Summary (42.2 vs 44.1; P < 0.005), numerically higher scores on the Mental Component Summary (39.5 vs 38.5; P = 0.145), significantly higher scores on the Migraine Disability Assessment (39.1 vs 34.0; P < 0.05), and significantly higher prevalence of depression symptoms (62% vs 47%; P < 0.001) and anxiety symptoms (42% vs 31%; P < 0.01). The ≥ 2 failures group versus the preventive-naive group also had significantly more functional impairment as assessed by mean numbers of migraine-specific missed work days (7.8 vs 4.3) and household activities days (14.3 vs 10.6) in the past 6 months (P < 0.001) as well as the prevalence of absenteeism (19% vs 13%), overall work impairment (53% vs 42%), and activity impairment (53% vs 47%) (all P < 0.05). Emergency department visits (0.7 vs 0.5; P = 0.001) and hospitalizations (0.5 vs 0.3; P < 0.001) in the past 6 months were significantly higher in the ≥ 2 failures group versus the preventive-naive group, while indirect costs (€13,720 vs €11,282) and the proportion of individuals with non-adherence during the past 7 days (73% vs 64%) were numerically higher. Increased burden, quality-of-life impairment, and functional impairment exist among individuals with migraine experiencing ≥ 4 MHDs and more treatment failures. While cause and directionality cannot be determined, these results suggest the need for effective preventive migraine treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Data are limited regarding the combined impact of headache frequency and failure of preventive medication (efficacy and/or tolerability) on the humanistic/economic burden of migraine.
METHODS
METHODS
A retrospective, cross-sectional analysis of 2020 National Health and Wellness Survey (NHWS) data was conducted. An opt-in online survey identified adults in France, Germany, Italy, Spain, and United Kingdom with self-reported physician-diagnosed migraine. Participants with ≥ 4 monthly headache days (MHDs) were stratified by prior preventive medication use/failure (preventive naive; 0-1 failure; ≥ 2 failures). Quality-of-life and economic outcomes were compared among groups using generalized linear modeling.
RESULTS
RESULTS
Among individuals with ≥ 4 MHDs (n = 1106), the NHWS identified 298 (27%) with ≥ 2 failures, 308 (28%) with 0-1 failure, and 500 (45%) as preventive naive. Individuals with ≥ 2 failures versus preventive-naive individuals had significantly lower scores on the 12-Item Short Form Survey Physical Component Summary (42.2 vs 44.1; P < 0.005), numerically higher scores on the Mental Component Summary (39.5 vs 38.5; P = 0.145), significantly higher scores on the Migraine Disability Assessment (39.1 vs 34.0; P < 0.05), and significantly higher prevalence of depression symptoms (62% vs 47%; P < 0.001) and anxiety symptoms (42% vs 31%; P < 0.01). The ≥ 2 failures group versus the preventive-naive group also had significantly more functional impairment as assessed by mean numbers of migraine-specific missed work days (7.8 vs 4.3) and household activities days (14.3 vs 10.6) in the past 6 months (P < 0.001) as well as the prevalence of absenteeism (19% vs 13%), overall work impairment (53% vs 42%), and activity impairment (53% vs 47%) (all P < 0.05). Emergency department visits (0.7 vs 0.5; P = 0.001) and hospitalizations (0.5 vs 0.3; P < 0.001) in the past 6 months were significantly higher in the ≥ 2 failures group versus the preventive-naive group, while indirect costs (€13,720 vs €11,282) and the proportion of individuals with non-adherence during the past 7 days (73% vs 64%) were numerically higher.
CONCLUSIONS
CONCLUSIONS
Increased burden, quality-of-life impairment, and functional impairment exist among individuals with migraine experiencing ≥ 4 MHDs and more treatment failures. While cause and directionality cannot be determined, these results suggest the need for effective preventive migraine treatments.
Identifiants
pubmed: 37612633
doi: 10.1186/s10194-023-01655-5
pii: 10.1186/s10194-023-01655-5
pmc: PMC10464178
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115Informations de copyright
© 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
Références
Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23:34
pubmed: 35410119
pmcid: 9004186
doi: 10.1186/s10194-022-01402-2
Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders, 3rd edn. Cephalalgia, vol. 38, p 1–211
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31:301–315
pubmed: 20813784
doi: 10.1177/0333102410381145
Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM et al (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59:1286–1299
pubmed: 31407321
pmcid: 6771487
doi: 10.1111/head.13613
Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB (2020) Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache 60:2340–2356
doi: 10.1111/head.13966
Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ et al (2021) Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 61:992–1003
pubmed: 34081791
doi: 10.1111/head.14154
Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P (2020) The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther 9:535–549
pubmed: 32542532
pmcid: 7606377
doi: 10.1007/s40120-020-00196-2
Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache 52:1456–1470
pubmed: 22830411
doi: 10.1111/j.1526-4610.2012.02223.x
Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41:638–645
pubmed: 11554951
doi: 10.1046/j.1526-4610.2001.041007638.x
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349
pubmed: 17261680
doi: 10.1212/01.wnl.0000252808.97649.21
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137
pubmed: 33267788
pmcid: 7708887
doi: 10.1186/s10194-020-01208-0
Katsarava Z, Buse DC, Manack AN, Lipton RB (2012) Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 16:86–92
pubmed: 22083262
doi: 10.1007/s11916-011-0233-z
World Health Organization. Headache disorders Geneva, Switzerland: World Health Organization; (2016) [April 6, 2016]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/headache-disorders .
Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485–1495
pubmed: 33773613
doi: 10.1016/S0140-6736(20)32160-7
Torres-Ferrús M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P (2017) When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia 37:104–113
pubmed: 26961321
doi: 10.1177/0333102416636055
Manack Adams A, Buse DC, Leroux E, Lanteri-Minet M, Sakai F, Matharu M et al (2023) Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study: methods and multi-country baseline findings for diagnosis rates and care. Cephalalgia 43:1–13
Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc 91:596–611
doi: 10.1016/j.mayocp.2016.02.013
Martelletti P, Schwedt TJ, Lanteri-Minet M, Quintana R, Carboni V, Diener HC et al (2018) My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 19:115
pubmed: 30482181
pmcid: 6755592
doi: 10.1186/s10194-018-0946-z
Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK (2019) Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm 25:46–59
pubmed: 30044691
Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19:82
pubmed: 30203163
pmcid: 6131678
doi: 10.1186/s10194-018-0907-6
Pozo-Rosich P, Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S et al (2021) Burden of migraine in patients with preventive treatment failure attending European headache specialist centers: real-world evidence from the BECOME study. Pain Ther 10:1691–1708
pubmed: 34643891
pmcid: 8586314
doi: 10.1007/s40122-021-00331-3
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40:373–383
pubmed: 3558716
doi: 10.1016/0021-9681(87)90171-8
Maruish ME (2011) User’s Manual for the SF-36v2 Health Survey, 3rd edn. Quality Metric Incorporated, Lincoln, RI
Montazeri A, Vahdaninia M, Mousavi SJ, Asadi-Lari M, Omidvari S, Tavousi M (2011) The 12-item medical outcomes study short form health survey version 2.0 (SF-12v2): a population-based validation study from Tehran, Iran. Health Qual Life Outcomes 9:12
pubmed: 21385359
pmcid: 3063185
doi: 10.1186/1477-7525-9-12
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736
pubmed: 21479777
pmcid: 3220807
doi: 10.1007/s11136-011-9903-x
Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56:S20–S28
pubmed: 11294956
doi: 10.1212/WNL.56.suppl_1.S20
Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613
pubmed: 11556941
pmcid: 1495268
doi: 10.1046/j.1525-1497.2001.016009606.x
Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097
pubmed: 16717171
doi: 10.1001/archinte.166.10.1092
Gupta S, Mehrotra S, Villalon CM, Garrelds IM, de Vries R, van Kats JP et al (2006) Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 530:107–116
pubmed: 16375887
doi: 10.1016/j.ejphar.2005.11.020
Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353–365
pubmed: 10146874
doi: 10.2165/00019053-199304050-00006
Unni EJ, Olson JL, Farris KB (2014) Revision and validation of Medication Adherence Reasons Scale (MAR-Scale). Curr Med Res Opin 30:211–221
pubmed: 24102296
doi: 10.1185/03007995.2013.851075
Bolge SC, Doan JF, Kannan H, Baran RW (2009) Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res 18:415–422
pubmed: 19288223
doi: 10.1007/s11136-009-9462-6
Finkelstein EA, Allaire BT, DiBonaventura MD, Burgess SM (2011) Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes. J Occup Environ Med 53:1025–1029
pubmed: 21866052
doi: 10.1097/JOM.0b013e318229aae4
Median hourly earnings, all employees (excluding apprentices) by sex: Eurostat; (2014) [April 8, 2021]. Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=earn_ses_pub2s&lang=en .
Stuchlik A. Wage developments in the euro area: European Parliamentary Research Service; (2015) [Available from: https://www.europarl.europa.eu/RegData/etudes/BRIE/2015/565884/EPRS_BRI(2015)565884_EN.pdf .
Cabrita J, Galli da Bino C (2013) Developments in collectively agreed working time 2012. European Foundation for the Improvement of Living and Working Conditions, Dublin, Ireland
Fosså SD, Dahl AA (2002) Short Form 36 and Hospital Anxiety and Depression Scale. A comparison based on patients with testicular cancer. J Psychosom Res 52:79–87
pubmed: 11832253
doi: 10.1016/S0022-3999(01)00308-7
Ware JE, Kosinski M, Keller SD (1995) SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales, 2nd edn. The Health Institute, New England Medical Center, Boston, MA
Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J (2019) Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther 8:203–216
pubmed: 31350710
pmcid: 6857199
doi: 10.1007/s40122-019-0133-1
Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, Braçe O, Colomina I, Blanch C et al (2020) Estimating the savings associated with a migraine-free life: results from the Spanish Atlas. Eur J Neurol 27:2616–2624
pubmed: 32643853
doi: 10.1111/ene.14431
Waliszewska-Prosół M, Straburzyński M, Czapińska-Ciepiela EK, Nowaczewska M, Gryglas-Dworak A, Budrewicz S (2023) Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort: results from “Migraine in Poland”—a nationwide cross-sectional survey. J Headache Pain 24:40
pubmed: 37041492
pmcid: 10091674
doi: 10.1186/s10194-023-01575-4
Gruenberger JB, Vietri J, Keininger DL, Mahler DA (2017) Greater dyspnea is associated with lower health-related quality of life among European patients with COPD. Int J Chron Obstruct Pulmon Dis 12:937–944
pubmed: 28360517
pmcid: 5365328
doi: 10.2147/COPD.S123744
Gupta S, Richard L, Forsythe A (2015) The humanistic and economic burden associated with increasing body mass index in the EU5. Diabetes Metab Syndr Obes 8:327–338
pubmed: 26229497
pmcid: 4516187
doi: 10.2147/DMSO.S83696
Gupta S, Isherwood G, Jones K, Van Impe K (2015) Assessing health status in informal schizophrenia caregivers compared with health status in non-caregivers and caregivers of other conditions. BMC Psychiatry 15:162
pubmed: 26194890
pmcid: 4509463
doi: 10.1186/s12888-015-0547-1
Gupta S, Ryvlin P, Faught E, Tsong W, Kwan P (2017) Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil. Epilepsia Open 2:199–213
pubmed: 29588949
pmcid: 5719850
doi: 10.1002/epi4.12050
Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D (2017) The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β(2)-agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim Care Respir Med 27:17
pubmed: 28270657
pmcid: 5434793
doi: 10.1038/s41533-017-0014-1
Wu M-J, Zhao K, Fils-Aime F (2022) Response rates of online surveys in published research: a meta-analysis. Comput Hum Behav Rep 7:100206
doi: 10.1016/j.chbr.2022.100206